Companies › Shanghai Chia Tai Tianqing Pharmaceutical Technology Development
8 active drug programs in 11 registered trials: 5 Phase 3, 3 Phase 2, 3 Phase 1; Oncology, Respiratory, Immunology, Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TQH2722 injection Humanized interleukin-4 receptor alpha (IL-4Rα) monoclonal antibody | IL4R | Phase 3 | Atopic Dermatitis; Seasonal Allergic Rhinitis | Nov 2026 |
| TQC2731 injection anti-TSLP monoclonal antibody; blocks TSLP signaling pathway and inhibits downstream cytok | TSLP | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Asthma; Chronic Obstructive Pulmonary Disease | Dec 2026 |
| TQB2868 Injection PD-L1 and TGF-β dual antibody | CD274, TGFB1 | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | May 2028 |
| LM-302 Injection anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Adenocarcinoma | Oct 2028 |
| TQB2825 Injection CD3/CD20 bispecific antibody | CD3, CD20 | Phase 2 | Diffuse Large Cell B-lymphoma | Feb 2028 |
| TQB6426 for Injection anti-GPC3 antibody-drug conjugate | GPC3 | Phase 1 | Advanced Malignancies | Aug 2027 |
| TQB2934 injection Bispecific antibody targeting BCMA and CD3 | BCMA, CD3E | Phase 1 | Systemic Light Chain Amyloidosis | Feb 2029 |
| TQB2922 injection Bispecific antibody against EGFR and c-Met | EGFR, MET | Phase 1 | Advanced Cancers | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06552520 | TQH2722 injection | Phase 3 | Atopic Dermatitis | Immunology | Sep 2025 |
| NCT07398859 | TQH2722 injection | Phase 2 | Seasonal Allergic Rhinitis | Immunology | Nov 2026 |
| NCT06707883 | TQC2731 injection | Phase 2 | Chronic Obstructive Pulmonary Disease | Respiratory | Dec 2026 |
| NCT07107256 | TQC2731 injection | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Respiratory | Mar 2027 |
| NCT07730190 | TQB6426 for Injection | Phase 1 | Advanced Malignancies | Oncology | Aug 2027 |
| NCT06829784 | TQC2731 injection | Phase 3 | Asthma | Respiratory | Dec 2027 |
| NCT06854445 | TQB2825 Injection | Phase 2 | Diffuse Large Cell B-lymphoma | Oncology | Feb 2028 |
| NCT07165951 | TQB2868 Injection | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | Oncology | May 2028 |
| NCT07385703 | LM-302 Injection | Phase 3 | Adenocarcinoma | Oncology | Oct 2028 |
| NCT07266116 | TQB2934 injection | Phase 1 | Systemic Light Chain Amyloidosis | Metabolic and endocrine | Feb 2029 |
| NCT07260708 | TQB2922 injection | Phase 1 | Advanced Cancers | Oncology | Dec 2029 |
Pierre Fabre Medicament Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Jiangsu Alphamab Biopharmaceuticals Dizal Pharmaceuticals Philogen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.